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Abstract: An offline t~d.imensional system combining a ral cardiac muscle cell membrane chromatography time-or-flight
mass spectrometry (CMC-TOF/MS) with a high performance liquid chromatogmphy time-oC-fIight mass spectrometry
(HPLCTOF/MS) was established for investigating the parent comJX>nents and metabolites in rat urine samples after
administration of the roots of Aconitum cannichaeli. On the basis of -the analysis of the first dimension. retention
components of the urine sample were collected into 30 fractions (one fraction per minute). Then offline analysis of the;:
second dimension was carried oui. 34 compounds including 24 parent alkaloids and 10 potential rnctabolites wcre identified
from the dosed rat urine. and then binding affinities of different compounds on cell membranes were compared and
influences of some functional groups on activity were estimated with the semi-quantification and curve fitting method. N.
a result. binding affinities decreased along with the process of dcacylation. debenzoylation and demethylation. which may
be related to the alleviation of toxicity in the procedure of herb processing or metarolism. Moreover. some minor
components in rat urine (Songorinc. 14-benzoylneoline. Deoxyaconitinc. ctc.) exerted relatively strong affinity on cell
membranes are 'NOrth exploring. The results delivered by the system suggest that the CMC can be appljed to in vivo study.
Keywords: cell membrane chromatography: high performance liquid chromatography: time-of-flight mass spectrometry;
two-dimensional system; Aconitum camlichaeli
I Introduction
Cell membrane chromatography (CMC), a biological chro-
matographic technique proposed by He' group in 1996 [I,
2], has been successfully applied to studying the interac·
tions between ligands and membrane receptors [3-5]. The
results obtained from CMC assay are consistent with those
from radioligand binding assay (RLA) significantly [6,7].
CMC has been proved to be an effective tool for screening
of active components targeting membrane receptors from
traditional Chinese medicines (TCMs) [8-12]. CMC, as an
approach to recognition of active components, combined
with other separation and identification techniques as well
as pharmacological verification trials, will provide another
way to rapidly discover target components from complex
system [13-15]. CMC has already been applied to investi-
gate the TCMs. In fact, the study of complex biological
samples is also count for much. Under the environment of
enzymes and body fluid, biotransformation will take place
once the drugs or TCMs are absorbed by the body, leading
to the changes of their pharmacological activity. Some
active components are metabolized into low active, even
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inactive prooucts, while some components of no obvious
pharmacological effect in vitro will beeome active. Biologi-
cal samples are extremely complicated. but CMC makes it
convenient to study the components of TCMs and their
metabolites in them.
We took rat urine samples after gavage administration of
the roots of Aconitum carmichaeli Debx. (Fuzi, in
Chinese) as an example to make use of CMC. Fuzi is one of
the most useful herbal medicines, which has been widely
used as an important ingredient in TCMs for their anti-
inflammatory, analgesic and cardiotonic effects [16, 171.
C,,-diterpenoid aconite alkaloids in Fuzi traditionally can be
divided into four major types according to Ihe substitute at
the C. or C.. position: diester-diterpenoid alkaloids (DDAs),
monoester-diterpenoid alkaloids (MDAs), alkylolamine-
diterpenoid alkaloids (ADAs) and other C,,-diterpenoid al-
kaloids [18-20]. Acetyl functions at the C. position in the
parent alkaloids, DDAs, are easily hydrolyzed to produce
MDAs, and then, the benzoyl or anisoyl functions at the
C" position is hydrolyzed to produce the final degradation
products, ADAs (Figure 1). The dctailed mechanism of the
metabolism of these alkaloids has searcely been reported. [n
rats, aconitine might be metabolized by CYP3A and
CYP1Al12 isoforrns in liver microsome, and O-demethyla-
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tion and N-deethylation were the main metabolic pathways 2 Experimental
[21] .
2.1 OIemicals and materials
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Figure 1 Skeleton of Cwditcrpcnoid aconite alkaloids in Fuzi.
It is not yet clear whether these alkaloids and metabolites
exhibit high or low toxicity, or they have additional bio-
chemical activities. It cannot be excluded that some minor
. cOffiJX>unds may also exert pharmacological effects and
therefore play a crucial role in clinical application [22].
DDAs, mainly, aconitine, hypaconitine and mesaconitine,
are well known active and toxic ingredients, while MDAs
show a much lower toxicity than that of DDAs. However,
the pharmacological studies showed that MDAs and ADAs
have significant active actions that would be the desired
effects [23,24]. So these structural analogs, alkaloids sha-
ring the common skeleton, may have similar pharmacologi-
cal effects. CMC can be used for identification of active
compounds from biological samples which contain both
herbs and metabolites.
In this paper, we have successfully established an offline
two-dimensional (2D) system, which combined a rat cardi-
ac muscle/CMC- time-of-flight mass spectrometry (TOFI
MS) with a high performance liquid chromatography time-
of-flight mass spectrometry (HPLC-TOF/MS). This system
was applied to investigate the parent drugs and metabolites
in rat urine samples after administration of Fuzi extract.
According to the total ions chromatogram (TIC) of CMC-
TOF/MS system, components of urine retained by CMC
were collected into 30 fractions. Then these samples were
analyzed by HPLC-TOF/MS system. On the basis of semi-
quantification of these samples, retention behaviors of each
compound on CMC were simulated. Finally, relationship
between the structure of compounds and affinity reflected
by CMC was evaluated. To our knowledge, it is the first
time that CMC was applied to in vivo studies .
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The herbal medicine Fuzi was purchased from Dekang Drug
Store (Shanghai. China) and authenticated by the Depart-
ment of Pharmacognosy, School of Pharmacy, Second Mil-
itary Medical University (Shanghai, China). HPLC-grade
acetonitrile was purchased from Merck (Darmstadt, Ger-
many) and formic acid was obtained from Fluka (Buchs,
Switzerland). Pure water was purchased from Hangzhou
Wahaha Group Co., Ltd. (Shanghai, China). Macro-
porous silica gel (5 I'm, 120 A) and empty column (2.1 mm
x 30 mm) were obtained from the Welch Materials Inc.
(Shanghai, China). All other reagents and solvents were of
analytical grade.
2.2 Preparation of Fuzi samples
Extracting solution of Fuzi was prepared using refluent
water extraction method. 50 g of sample was placed into a
1000 mL round bottomed flask. 500 mL pure water (10
times their total weight) was added and then decocted to
boil keeping for 2 h. The extracted solution was filtered
through four layers gauze. To the filtrate, 1000 mL ethanol
was added, at a filtrate/ethanol ratio of 1 : 2 (v/v) to pre-
cipitate the polysaccharide and protein. This sample was
kept overnight at 4 'C and then filtered through two layers
filter paper, and the filtrate was evaporated to dryness
under reduced pressure with a rotary evaporator at 60 'C .
The residue was dissolved in water to obtain an oral solution
of Fuzi with a concentration of 5 g/ mL (crude drugs).
From the above oral solution, 0.2 mL was diluted and made
up to 25 mL by addition of water. The diluted sample solu-
tion (FZ) was filtered through aD. 22 I'm membrane before
use. An aliquot of 5 f'L of each sample was injected into the
HPLC system.
2.3 Collection of urine samples
Four male Sprague-Dawley rats (200 - 250 g body weight)
were provided by the Experimental Animal Center, Second
Military Medical University (Shanghai, China). The ani-
mals were fasted for 12 h with free access to water before
the experiments. Then they were housed in separate meta-
bolic cages with free access to water. Blank urine (UOA ,
UO., UOe and UOD ) of each rat was collected during a 12 h
collection period, after which the rats were given regular
food and water for a week. Then the rats were fasted for
12 h with free access to water, and administered Fuzi
extract orally at a single dose of 50 g/kg. Post dose urine
(UIA , UI., Ulc and UID ) was collected from each rat by
the 12 h urine collection procedure. The experiment was
conducted in accordance with the National Institute of
Health guidelines regarding the principles of animal care
(2004).
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2.4 Pretreatment of urine samples
All urine samples were centrifuged at 10800 rpm for 10 min
and the supernatant obtained was stored at - 20'C until
additional extraction and analysis. 100 f'L of each blank
urine sample was mixed into a 400 f'L mixture of blank
urine (UOM ), and the same steps were conducted to make
mixed dosed urine (UlM ). A volume of 800 f'L of methanol
was added to the urine sample (UOM and UIM • separately).
and the mixture was vortex- mixed for 2 min and then cen-
trifuged at 10800 rpm for 10 min. Then the supernatant was
evaporated to dryness under a stream of N, gas. The residue
was redissolved in 80 f'L pure water. and an aliquot of 5 f'L
was injected directly into the CMC system. From the above
concentrated urine sample. 10 f'L was diluted and made up
to 500 f'L by addition of pure water. An aliquot of 5 f'L of
diluted sample was injecte<t into the HPLC system.
2.5 Rat canIiac lIJIlSClelCMC module
Male Sprague-Dawley rats (200 - 250 g body weight) were
from the Experimental Animal Center, Second Military
Medical University (Shanghai, China). The rat cardiac
muscle cell membrane was prepared as described [13.25.
26). After cervical dislocation. the heart of rat was harves-
ted immediately and the heart atrium was removed. The
cardiac muscular tissue was immerged into pre-cooled nor-
mal saline to wash out the bloodiness. After cutting into
pieces in 10 mL pre-cooled normal saline. the tissue was put
into a glass homogenizer for homogenizing. The homoge-
nate was then centrifuged at 3000 x g for 10 min. 10 mL
Tris-HCI (pH 7.4, 50 mM) was added to the pellet to pro-
duce a cell suspension, which was ruptured by sonication for
30 min immediately. The resulting suspension was vortex-
mixed and clarified by centrifugation at 1000 x g for 10
min. The pellet was discarded. and the suspension was re-
covered by centrifugation at 12000 Xg for 20 min. The pel-
let was resuspended in 10 mL phosphate buffer saline (pH
7.4. 5OmM) and cell membranes were collected by centrif-
ugation at 12000 x g for 20 min. The pellet was resuspended
in 5 mL distilled water. All the above operations were con-
ducted under conditions at 4 'C .
Cell membrane stationary phase (CMSP) was prepared
according to literature [1.2]. Briefly. 0.15 g silica was
activated at 12O"C for 30 min and used as a carrier. It was
then homogenized with the cell membrane suspension.
i. e.• the mixture was slowly added to it under a vacuum
and with agitation at 4 ·C. The mixture obtained was
packed into the column using a wet method to yield a CMSP
column (2.1 mm X30 mm. 5 f'm). This CMC module was
validated by negative and positive controls. They were solu-
tions of salvianolic acid B (SAB). furosemide (FR). dobu-
tamine (DB) and phentolamine (PT), with concentration
of 0.5 mglmL. which were prepared separately by dissol-
ving in normal saline. The life-span of this CMC column
was about 5 days under a continuous usage.
2.6 CMC-TOF/MS system
The analysis of urine sample on cell membrane chromatog-
raphy system was performed on an Agilent 1100 series
HPLC system (Agilent Corp., Germany) consisting of a
quaternary solvent delivery system. a thermostatically con-
trolled column apartment and a diode array detector. Chro-
matographic separation was carried out on a rat cardiac
musclelCMC column (2. I mm x 30 mm, 5 f'm) at 37 ·C.
The mobile phase was 10 mM ammonium acetate solution at
a flow rate of 0.2 mUmin. Then it totally flowed into the
mass spectrometer source. The DAD wavelength was
230 nm for urine sample, 330 nm for FR and 280 nm for
others.
Detection was performed by an Agilent orthogonal TOFI
MS (Agilent Corp.• USA) equipped with an ESI interface.
The TOF/MS analysis was performed using full scan mode
and mass range was set at m/z 100 - 1000 in positive ion
mode. The conditions of ESI source were as follows: drying
gas (N,) flow rate. 9 Umin; drying gas temperature.
35O'C; Nebulizer, 35 psig; capillary voltage. 4000 V; frag-
mentor voltage, 180 V; skimmer voltage. 60 V; octopole RF.
250 V. Tuning mix (GI969-85lXXl. Agilent Corp.• USA) was
used for lock mass calibration in the assay.
Eluate of the dosed urine (UIM ) on CMC system within
30 min was collected as one fraction per minute. In all. 30
fractions were collected and labeled as R, -Roo .
2.7 HPLC-TOF/MS system
The analysis of samples (FZ, UOM , UI M • R,-Roo) was per-
formed on an Agilent 1290 series HPLC system (Agilent
Corp.• USA) consisting of a binary solvent delivery system
and a thermostatically controlled column apartment. Chro-
matographic separation was carried out on an Agilent ZOR-
BAX SB-C18 column (4.6 mm X 150 mm, 5 f'm) at 25·C.
The mobile phase consisted of O. I % aqueous formic acid
(v/v) (A) and acetonitrile (B). using a gradient elution of
5% - 25% B at 0 - 25 min. 25% - 45% B at 25 - 35 min.
45% - 45% Bat 35 - 40 min. Afterwards. the column was
riused for 5 min with 95% B. the B content lowered to 5%
over 2 min, and the column was re-equilibrated for 10 min.
The flow rate was kept at O. 8 mUmin. and a post column
split was used to maintain a flow rate of 0.3 mUmin into
the mass spectrometer source to obtain good nebulization
efficiency.
Detection was performed by an Agilent 6538 UHD Accu-
rate-Mass Q-TOF/MS (Agilent Corp.. USA) equipped
with an ESI interface. The TOF/MS analysis was per-
formed using full scan mode and mass range was set at m/z
100 - 1000 in positive ion mode. The conditions of ESI
source were as follows: drying gas (N,) flow rate,
11 Umin; drying gas temperature, 350 'C; Nebulizer. 45
psig; capillary voltage. 4000 V; fragmentor voltage,
dynamic adjustment from 120 to 385 V; skimmer voltage,
45 V; octopole RF. 250 V. AU the data were processed by
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Agilent MassHunter Software Ver. B. 02. 00. Tuning mix
(01969-85000. Agilent Corp., USA) was used for lock
mass calibration in our assay.
Parent components and metabolites were identified
according to the analysis of FZ, UOM and U1M • Then each
compound was extracted from R1 - Roo using the extract ion
chromatography (E/C) mode.
3 Results and discussion
3.1 Validation of CMC module
Salvianolic acid B (antioxidants) and furosemide (diuretic)
were used as negative controls and dobutamine (~1 adreno-
ceptor agonists) and phentolamine (0 adrenoreceptor bloc-
ker) were used as positive controls to validate the specifica-
tion of this CMC module. Their retention behavior was
compared and the results are shown in Figure 2. SAB and
FR could not be retained on rat cardiac musclelCMC mod-
ule. However, DB and PT could be retained obviously. and
their retention time was 5.77 min and 10.17 min, respec·
tively. It indicated that this CMC module could selectively
retain the cornJX>nents that act on Q adrenoreceptor or ~
adrenoceptor. This CMC module could be used for screen-
ing such components from TCM preliminarily.
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Figure 2 Chromatograms of the negative controls and positive controls on the rat cardiac musclelCMC module. A, SAB;
B. FR; C, DB; D, PT.
3.2 Collection of fractions
At present, various two-dimensional systems have been
established, which combined CMC as the first dimension
and HPLC- MS or GC- MS as the second dimension [10-15].
On the basis of the analysis of the first dimension. retention
components were collected into many fractions. Then off-
line or online analysis of the second dimension was carried
out. UV detectors are often used as the detection methods
of the CMC systems. However, they may not be suitable
for the biological samples for the concentrations of compo-
nents are too low or some compounds are of weak UV
absorption. It is difficult to detect the DDAs in vivo by UV
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detector because of the low level of concentration and rapid
biodegradation [23]. and the degradation products show
weaker UV absorbance than the pa)"ent alkaloids. However,
specific detection by mF/MS techniques could provide
determination of these alkaloids.
We used both UV and mF/MS to determine the urine
samples with the purpose of collecting all the retained com-
ponents. The ultraviolet spectrum and the total ions chro-
matogram (TIC) of the dosed urine (U1M ) are shown in
Figure 3A and 3B respectively. Compared with the ultravi·
olet spectrum, the TIC indicated more information due to
the high sensitivity of the mF/MS detector. There were
many compounds retained by the CMC within 30 min which
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were demonstrated in the TIC, while it was almost a
straight line in the ultraviolet spectrum after 5 min. If we
only collected and analyzed the components within 5 min,
we might lose much information, because the binding affin-
ity shows a positive correlation with the retention time
according to the principle of cell membrane chromatogra-
phy. With the purpose of comprehensive two-dimensional
chromatography, the more fractions collected within 30
min, the more information would be obtained. Fractions
were collected each minute, totally 30 fractions. Taking in-
to account the dead volume of the system and the time de-
layed of the eluent from detection to collection. collection
was delayed for 0.5 min, i. e. fraction 0.5 min to 1. 5 min
was collected and labeled as R" fraction 1. 5 min to 2.5
min was collected and labeled as R;" and so on.
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Figm-e 3 The ultraviolet spectrum and the TIC of the dosed urine (UI M ) on the cell membrane chromatography system.
A, HPLC-DAD spectrum of UlMmonitored at 230 run, B, HPLCTOF/MS TIC of VIM'
3.3 ldentiflcatloo or ooulpo,ails
The typical base peak chromatograms (BPes) of the Fuzi
extract (FZ), the dosed urine (VIM) and the blank urine
(VOM ) are shown in Figure 4A, 4B and 4C respectively.
According to our previous work [27), 24 parent compo-
nents and 10 potential metabolites were identified. The
identification results are shown in Thble 1. This provides a
foundation for further identification of active compounds
from biological samples.
3.4 Simulatloo or e1ut1oo CW'Ves
A total of 1020 (34 x 30) extracted ion chromatograms
(EICs) were obtained by extracting 34 compounds from 30
collected fractions (R,-R;,o ). According to the Q.TOF
semi-quantitative analysis of the fractions, the peak areas
of target compounds in EICs were recorded. Then 34 scat·
ter plots, with normalized peak area on the vertical axis
and serial number of collected fraction on the horizontal
axis, were finished. Actually, the serial number of fraction
represents the retention time of fraction on CMC column,
i. e., the retention time of corresponding constituent, so
the scatter graph of a compound is the simulated elution
curve of it on the CMC system.
Take the component 06 (Benzoylaconitine, [M + H j'
mlz 604.3122) as an example. EICs were obtained by ex-
tracting mlz 604.3122 ( ± 5 ppm) from 30 collected frac-
tions. Consequently, the compound C16 can be detected in
the collected fractions R;,-R15 , and had the maximum peak
area in fraction RIO (Figure 5A). It cannot be detected in
fractions RI - R, and R... R;,o, so the peak areas of C16 were
regarded as a in them. Then the simulated elution curve of
C16 on the CMC system was obtained by plotting the nor-
malized peak area versus serial number of collected fraction
(Figure 5B). Thble 2 gives a concise and intuitional descrip·
tion of retention behavior of the 34 compounds on the CMC
system. Peaks on CMC column were broadened from Start
time to End time, and most of them were tailing peaks.
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F1gIre 4 The typical base peak chromatograms (BPes) of the Fuzi extract (FZ), the dooed urine (Ul.) and the blank urine (va.).
A, BPC of FZ; B, BPC of Ul.; C, BPC of va..
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Figure 5 Process of simulating the scatter plot of C16 (Benzoylaconitine) on the CMC system. At EICs of Ua-Vls by extracting
mlz 604.3122 ( ± 5 ppm); B, simulated elution curve of C16.
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1ibIe 1 Identification of the parent compounds and the potential metabolites from the dosed rat urine
ID RT (min) [M+ HI' m/z Formula Identification
Cl 4.862 394.2593 c"H"NQ; Karakolidine
C2 5.495 394.2593 c"H"NQ; Chuanfumine
C3 8.093 424.2699 c"H"NC\ Senbusine
C4 8.442 486.2703 c"H"NC\ Mesaconine
C5 8.861 364.2488 C"H"No. 16-fl.hydroxycardiopetaline
C5 9.228 424.2699 c"H"NC\ Senbusine
Cl 9.861 408.2750 c"H"NQ; Isotalatizidine
C8 10.898 358.2382 c,,!io,No, Songorine
C9 12.7ffl 454.2805 c"H"No, Fuziline
ClO 13.846 438.2856 c" H"NQ; Neoline
C11 16.443 422.2906 c"H"NC\ Talatizamine
C12 18.976 452.2646 c,. H"No, Chasmanine
Q3 21.104 464.3012 c"H.,NC\ 14-acetyltalatizamine
C14 21.683 606.2908 c" H"NO" 14-benzoyl-10-OH-rnesaconine
Cl5 26.562 590.2965 c" H"No" Benzoylme:saconine
C16 28.909 604.3122 c"H"No" Benzoylaconitine
C17 30.077 574.3016 C"H"NC\ BenzoyLhypaconitine
C18 31.376 558.3067 c" H"NQ; 14-benzoyl-3,I3-deoxyaconine
CI9 31.594 646.3227 c,. H.,NO" Aconitine
C20 31.856 586.3173 c" H.,No. Benzoyldeoxyaconitine
C21 32.991 542.3118 c" H"No, 14-benzoylneoline
C22 35.131 616.3122 c" H"No" Hypaconitine
C23 35.633 600.3173 c"H.,NC\ 13-deoxyhypaconitine
C24 37.172 630.3278 Co. H.,No,. Deoxyaconitine
MI 6.237 424.2699 c"H"NC\ Demethylated. metabolite of neoline
M2 6.816 394.2593 c"H"NQ; Demethylatc:d metabolite of isotalatizidine
M3 8.541 394.2593 c"H"NC\ Demethylated metabolite of isotalatizidine
M4 8.999 336.2175 C'9Hz,NO. Unknown
M5 12.470 424.2699 c"H"NC\ Isomer of demethylated metabolite of neoLine
M6 13.267 408.2750 c" H"NQ; Demethylated metabolite of talatizamine
M7 15.821 450.2856 c" H"NC\ Demethylated metabolite of 14-acetyitaiatizamine
M8 . 28.418 574.3016 c" H"NC\ Demethylated metabolite of benzoyldeoxyaconitine
M9 32.195 586.2809 c" H., NC>" Unknown
MlO 35.142 618.2914 c"H"No" Demethylated metabolite of mesaconitine
1lIbIe Z Retention behavior of the 34 compounds on tbe CMC system
ID Start (min) RToc:· End (min) ID Start (min) RToc:· End (min)
Cl 4 5 30 C18 21 23 25
C2 10 12 27 C19 14 15 21
C3 6 7 20 C20 17 18 21
C4 4 5 11 C21 24 25 30
C5 13 17 30 C22 19 22 27
C5 9 10 15 C23 23 24 26
Cl 11 14 23 C24 22 25 30
C8 25 25 30 MI 3 5 14
C9 7 8 25 M2 6 7 25
CI0 9 11 24 M3 9 10 13
C11 22 24 30 M4 6 7 18
C12 22 23 25 M5 7 8 15
C13 22 24 30 M6 17 19 30
C14 4 5 8 M7 14 16 23
C15 6 7 16 M8 10 12 14
CI6 8 10 15 M9 11 13 14
C17 14 16 26 MlO 20 21 25
• Retention time was supposed to be the number of fraction which had the maxirraun peak area.
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3.5 Evaluation of slnJcture activity relationship
According to the principle of cell membrane chromatogra-
phy. longer retention time indicates stronger binding
affinity. As shown in Table 2, different components had
different retention time. For instance, the components
CS, C21 and C24 had the maximum retention time of
about 25 min, while the C1, C4, C14 and Ml had the
minimum retention time of about 5 min. These differences
may attribute to the diversity of their structures. So the re-
lationship between the structure of compounds and binding
affinity reflected by CMC-in other words, pharmacology
activity-was evaluated.
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Figure 6 Simulated elution curves of certain ,compounds on the CMC system. A, C19 (Aconitine); B. C16 (Benzoylaconitine); C,
C22 {Hypaconitine}; D, C17 (Benzoylhypaconitine); E, C15 (Benzoylmesaconine); F, C4 (Mesaconine); G, Cl {Isotalatizidine};
H, M2; I, M3; J, CIO (Neoline); K, MI; L, MS.
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can exhibit activity or toxicity and, therefore. playa key
role in Fuzi. This work also demonstrates, for the first
time, that the cell membrane chromatography can be
applied to in vivo study.
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